TrialMedicine2026

Efficacy and safety of imeglimin hydrochloride for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: Single-center, single-arm phase 2 (IMELD study).

Hiroki Yamada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.